334792-52-8

Basic information

• Product Name: METHYL 3-BROMO-5-FLUOROBENZOATE
• Synonyms: METHYL 3-BROMO-5-FLUOROBENZOATE;3-bromo-5-fluorobenzoate
• CAS NO: 334792-52-8
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.03
• Product Categories: Acids & Esters;Bromine Compounds;Fluorine Compounds
• Mol File: 334792-52-8.mol

Chemical Properties

• Boiling Point: 251.6±25.0℃ (760 Torr)
• Flash Point: 106.0±23.2℃
• Appearance: /
• Density: 1.577±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.02mmHg at 25°C
• Refractive Index: 1.5345
• Storage Temp.: Room temperature.
• CAS DataBase Reference: METHYL 3-BROMO-5-FLUOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-BROMO-5-FLUOROBENZOATE(334792-52-8)
• EPA Substance Registry System: METHYL 3-BROMO-5-FLUOROBENZOATE(334792-52-8)

Safety Data

• Hazard Codes: T
• Statements: 25-36
• Safety Statements: 26-45
• RIDADR: UN2810
• Hazardous Substances Data: 334792-52-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 3-BROMO-5-FLUOROBENZOATE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties, contributing to advancements in medicine.
Used in Agrochemical Industry:
In the agrochemical sector, METHYL 3-BROMO-5-FLUOROBENZOATE serves as a key intermediate in the production of agrochemicals. Its incorporation aids in the creation of effective compounds for pest control and crop protection, enhancing agricultural productivity.
Used in Organic Synthesis:
METHYL 3-BROMO-5-FLUOROBENZOATE is utilized as a building block in organic synthesis. It plays a crucial role in the development of a variety of chemical compounds, expanding the scope of chemical research and innovation.

InChI:InChI=1/C8H6BrFO2/c1-12-8(11)5-2-6(9)4-7(10)3-5/h2-4H,1H3

Upstream product

• 176548-70-2 3-bromo-5-fluorobenzoic acid 
• 144-55-8 sodium hydrogencarbonate 
• 67-56-1 methanol 
• 887266-90-2 3-bromo-5-fluoro-benzoyl chloride 
• 1435-51-4 1,3-dibromo-5-fluorobenzene 
• 179898-34-1 3-bromo-5-fluorobenzonitrile 

Downstream Products

• 914944-23-3 methyl 3-fluoro-5-(2-trimethylsilylethynyl)benzoate 
• 1403612-33-8 methyl 3-cyano-5-fluoro-4-iodobenzoate 
• 1403612-35-0 N'-[(3-cyano-5-fluoro-4-iodobenzoyl)oxy]-5-fluoropyridine-2-carboximidamide 
• 1403612-36-1 3-fluoro-5-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]-2-iodobenzonitrile 
• 1403612-34-9 3-cyano-5-fluoro-4-iodobenzoic acid 
• 886732-29-2 methyl 3-cyano-5-fluorobenzoate 

Relevant articles and documents

METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS

In one aspect, the invention relates to 4-substituted benzoylpiperazine-1-substituted carbonyls, derivatives thereof, and related compounds; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g., various tumors and cancers, associated with β-catenin/BCL9 protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

SYNTHESIS, CRYSTAL STRUCTURE, AND DFT STUDY OF METHYL 3-FLUORO-5-(4,4,5,5-TETRAMETHYL-1,3,2- DIOXABOROLAN-2-YL)BENZOATE AND (2-METHYL-4- (4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL) PHENYL)(PYRROLIDIN-1-YL)METHANONE COMPOUNDS

Abstract: Methyl 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate and (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(pyrrolidin-1-yl)methanone are boric acid ester intermediates with benzene rings. In this paper, the titl

Structure-Based Design of 1,4-Dibenzoylpiperazines as β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction Inhibitors

A small-molecule inhibitor with a 1,4-dibenzoylpiperazine scaffold was designed to match the critical binding elements in the β-catenin/B-cell lymphoma 9 (BCL9) protein-protein interaction interface. Inhibitor optimization led to a potent inhibitor that can disrupt the β-catenin/BCL9 interaction and exhibit 98-fold selectivity over the β-catenin/cadherin interaction. The binding mode of new inhibitors was characterized by structure-activity relationships and site-directed mutagenesis studies. Cell-based studies demonstrated that this series of inhibitors can selectively suppress canonical Wnt signaling and inhibit growth of Wnt/β-catenin-dependent cancer cells.

TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS

The present invention provides tetrahydropyridopyrimidines and tetrahydropyridopyridines having the general formula (I) wherein R1, R2, U, W, X, Y and Z are as described herein, as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment and prophylaxis of hepatitis B virus infections.

Discovery and characterization of AZD9272 and AZD6538 - Two novel mGluR5 negative allosteric modulators selected for clinical development

AZD9272 and AZD6538 are two novel mGluR5 negative allosteric modulators selected for further clinical development. An initial high-throughput screening revealed leads with promising profiles, which were further optimized by minor, yet indispensable, structural modifications to bring forth these drug candidates. Advantageously, both compounds may be synthesized in as little as one step. Both are highly potent and selective for the human as well as the rat mGluR5 where they interact at the same binding site than MPEP. They are orally available, allow for long interval administration due to a high metabolic stability and long half-lives in rats and permeate the blood brain barrier to a high extent. AZD9272 has progressed into phase I clinical studies.

m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM

An object of the present invention is to provide m-substituted benzoic acid derivatives having integrin αvβ3 antagonistic activity. The derivatives according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof, which are useful for the treatment or prevention of cardiovascular diseases, angiogenesis-related diseases, cerebrovascular diseases, cancers and metastasis thereof, immunological diseases, osteopathy and other diseases: wherein A represents an optionally substituted heterocyclic group containing two nitrogen atoms, a bicylic group or the like; D represents a bond, >NR4, >CR5R6, O, S, or -NR4-CR5R6-; X represents CH or N; R7 and R8 represent hydroxyl, alkyl or the like; Q represents >C=O or the like; R9 represents hydrogen, alkyl or the like; J represents a bond or alkylene; R10 represents optionally substituted hydroxyl, amino or the like; R11 represents hydrogen, alkyl or the like; m is 0 to 5; n is 0 to 4; and p and q are each 0 to 3.